Target Price | $42.25 |
Price | $29.58 |
Potential |
42.83%
register free of charge
|
Number of Estimates | 4 |
4 Analysts have issued a price target Collegium Pharmaceutical, Inc. 2025 .
The average Collegium Pharmaceutical, Inc. target price is $42.25.
This is
42.83%
register free of charge
$50.00
69.03%
register free of charge
$37.00
25.08%
register free of charge
|
|
A rating was issued by 5 analysts: 3 Analysts recommend Collegium Pharmaceutical, Inc. to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Collegium Pharmaceutical, Inc. stock has an average upside potential 2025 of
42.83%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 566.77 | 628.98 |
22.17% | 10.98% | |
EBITDA Margin | 57.29% | 63.10% |
30.43% | 10.14% | |
Net Margin | 7.34% | 9.53% |
242.69% | 29.91% |
5 Analysts have issued a sales forecast Collegium Pharmaceutical, Inc. 2024 . The average Collegium Pharmaceutical, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Collegium Pharmaceutical, Inc. EBITDA forecast 2024. The average Collegium Pharmaceutical, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Collegium Pharmaceutical, Inc. Analysts have issued a net profit forecast 2024. The average Collegium Pharmaceutical, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | 1.29 | 1.86 |
274.32% | 44.19% | |
P/E | 15.90 | |
EV/Sales | 2.87 |
3 Analysts have issued a Collegium Pharmaceutical, Inc. forecast for earnings per share. The average Collegium Pharmaceutical, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Collegium Pharmaceutical, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Collegium Pharmaceutical, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.